One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET
|
23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy®...
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first...
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical...
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding...
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024 16:45 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024 07:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in...
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024 07:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder...